Testing genes and blood chemistry in MEN1 pancreatic tumors
Part of Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at blood chemistry (metabolomics) and genetic information in people who have MEN1, especially if they are being evaluated for pancreatic neuroendocrine tumors. It may help doctors better diagnose these tumors by finding patterns in test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed MEN1 diagnosis (by family history, clinical evaluation, or genetic testing)
- You must not have a prior history of pancreatic neuroendocrine tumors
- You must be willing to provide samples/test results for gene and blood-chemistry testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Multiple Endocrine Neoplasia type 1 (MEN1) over time, including those with symptoms, certain isolated hormone gland problems, and people without symptoms who have the MEN1 gene change. It may help doctors learn how MEN1 starts and progresses so care can be better timed and personalized.
This study is testing a new blood test to see if it can help diagnose neuroendocrine tumors in people with MEN1, a genetic condition that increases the risk of these tumors. The test looks for a protein called hPG80 (progastrin) and may help doctors find tumors earlier.
This study follows people who have Multiple Endocrine Neoplasia type 1 (MEN1), a genetic condition that can cause tumors in hormone glands. It aims to monitor symptoms and lesions over time to better understand how the condition progresses and how to manage it.
This trial is building a database to better understand Multiple Endocrine Neoplasia Type 1 (MEN1). If you have been diagnosed with MEN1, you may be eligible to help researchers learn more about the condition.
This study offers genetic (inherited) testing for people with pancreatic neuroendocrine neoplasms. The goal is to see who may have a genetic predisposition, which can help guide medical care and family risk.
This study looks at a special analysis of your blood (called cfDNA fragmentomics) to help find and tell apart certain early pancreatic tumors. If you’re having surgery for one of the listed solid pancreatic tumors, this trial may use your blood samples to improve diagnosis.
Hear when a new Multiple Endocrine Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.